A Prospective, Multicenter, Single Arm Trial Evaluating the BARD Lutonix Drug-Coated Balloon (LTX DCB) for Treatment of Femoropopliteal Arteries (LEVANT China)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Paclitaxel (Primary)
- Indications Peripheral arterial disorders
- Focus Adverse reactions; Therapeutic Use
- Acronyms LEVANT China
- Sponsors C.R. Bard
- 20 Oct 2017 Planned End Date changed from 1 Jun 2019 to 1 Sep 2019.
- 20 Oct 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Sep 2018.
- 20 Oct 2017 Status changed from recruiting to active, no longer recruiting.